Toutes les études
RecrutementPHASE2INTERVENTIONNEL

NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)

This study is looking at a new medicine called NS-089/NCNP-02 for boys aged 4 to 14 who have Duchenne muscular dystrophy (DMD). Specifically, it's for boys whose DMD is caused by a genetic change that can be treated by something called 'exon 44 skipping'. The study aims to find out if this new medicine is safe and how well it works. Participants will receive the medicine through a drip (IV infusion) once a week. The study is divided into two parts, with a small group of boys in the first part, and then more boys joining in the second part to gather more information. All participants will be able to walk without help.

En un coup d'œil

Statut
Recrutement
Phase
PHASE2
Sponsor
NS Pharma, Inc.
Objectif d'inscription
20
Démarrer
22 févr. 2024
Achèvement estimé
11 Sep 2026

De quoi parle cette étude ?

Duchenne muscular dystrophy (DMD) is a serious genetic condition that causes muscles to become weaker over time. This study is testing a new medicine called NS-089/NCNP-02. The goal of this medicine is to help correct a specific genetic problem in some boys with DMD, which involves 'skipping' a part of their gene called exon 44. By doing this, the hope is to help the body make a more functional dystrophin protein, which is vital for healthy muscles.

This is a 'Phase 2' study, meaning researchers are looking closely at how safe the medicine is and starting to see if it has a positive effect. It's also 'open-label', which means both the patients and the doctors will know they are receiving the study medicine. The medicine will be given to boys aged 4 to 14 who can still walk on their own.

The study is important because it could potentially offer a new treatment option for boys with DMD who have this specific genetic change. Finding effective treatments is a crucial step towards improving the lives of individuals living with this challenging condition.

Points clés

  • This study is testing an experimental medicine (NS-089/NCNP-02) for DMD.
  • It's for boys aged 4-14 with a specific genetic change (exon 44 skipping) who can walk unassisted.
  • The medicine is given weekly through a drip.
  • The study aims to understand the medicine's safety and effectiveness.
  • Participation involves regular hospital visits for assessments and treatment.

Qui peut être éligible ?

To join this study, boys must be between 4 and 14 years old. They need to have a confirmed diagnosis of Duchenne muscular dystrophy (DMD) caused by a specific genetic change (mutation) that can be treated by 'exon 44 skipping'. It's also important that they can walk by themselves without any walking aids and can complete a specific walking test quickly.

Participants must have been on a steady dose of steroid medication for at least three months before starting the study and expect to continue that dose throughout. There are also some reasons why someone might not be able to join. For example, if they have certain heart problems, have used particular medications or other experimental treatments recently, or have had surgery in the last three months.

They also can't have participated in a previous study of this exact medicine (NS-089/NCNP-02) or received other similar 'exon skipping' treatments in the past year. There are other criteria too, so the study team will check everything carefully.

Cet étude pourrait-elle vous convenir ?

Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.

  1. Is the boy between 4 and 14 years old?
  2. Does he have Duchenne muscular dystrophy with an 'exon 44 skipping' genetic change?
  3. Can he walk on his own without any walking aids?
  4. Has he been on a stable dose of steroid medication for at least 3 months?
  5. Has he avoided certain other medications or experimental treatments recently?
Répondez à chaque question pour voir votre résultat.

En quoi consiste la participation ?

If you decide to take part, the study involves weekly visits to receive the medicine, NS-089/NCNP-02, through a drip into a vein (IV infusion). The total duration of your involvement will depend on which part of the study you join.

Before treatment starts, there will be screening visits to ensure you meet all the requirements. During the study, you'll have regular check-ups, assessments of your muscle strength and movement (like walking tests), and possibly blood tests to see how the medicine is affecting you. All these visits and tests are designed to monitor your health and how the medicine is working. The study is divided into two parts, so some participants will be involved for longer than others.

Risques et avantages potentiels

Participating in a clinical trial may offer potential benefits, such as access to a new treatment that isn't widely available. However, there are also potential risks, as the medicine is still being studied, and not all side effects or benefits are fully known. You might experience side effects, some of which could be unexpected. It's important to remember that you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (25)

  • Children's Hospital Colorado
    Code postal vérifié
    Aurora, États-Unis· Recrutement
  • Rare Disease Research, LLC - FL
    Code postal vérifié
    Kissimmee, United States· Recrutement
  • Rare Disease Research
    Code postal vérifié
    Atlanta, États-Unis· Recrutement
  • Ann and Robert H. Lurie Children's Hospital of Chicago
    Code postal vérifié
    Chicago, États-Unis· Recrutement
  • University of Kansas Medical Center (KUMC)
    Code postal vérifié
    Kansas City, États-Unis· Recrutement
  • Cincinnati Children's Hospital Medical Center
    Code postal vérifié
    Cincinnati, United States· Recrutement
  • The Children's Hospital of Philadelphia (CHOP)
    Code postal vérifié
    Philadelphie, États-Unis· Recrutement
  • University of Pittsburgh School of Medicine
    Code postal vérifié
    Pittsburgh, United States· Recrutement
  • UT Southwestern/Children's Health
    Code postal vérifié
    Dallas, United States· Recrutement
  • Virginia Commonwealth University Health System
    Code postal vérifié
    Richmond, United States· Recrutement
  • Perth Children's Hospital
    Code postal vérifié
    Nedlands, Australia· Pas encore en recrutement
  • Alberta Children's Hospital
    Code postal vérifié
    Calgary, Canada· Pas encore en recrutement

Questions fréquentes

What is Duchenne muscular dystrophy (DMD)?

DMD is a genetic condition that causes muscles to get weaker over time, making it harder to move around.

What does 'exon 44 skipping' mean?

It's a way the new medicine tries to fix a specific error in the DNA of some boys with DMD, helping their bodies make a vital muscle protein.

Comment le médicament sera-t-il administré ?

The medicine, NS-089/NCNP-02, will be given through a drip into a vein (an IV infusion) once a week.

Can I join if I use a wheelchair?

No, this study is specifically for boys who can still walk independently without any help.

What is a 'Phase 2' study?

Phase 2 studies are designed to see if a new medicine is safe and starts to show a positive effect, building on earlier safety tests.

Comment en savoir plus

Trial info

Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.

Intéressé à participer ?

Inscrivez votre intérêt

Partagez vos coordonnées et l'équipe de recherche pour "NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy … vous contactera si vous êtes éligible. Consultez toujours votre médecin avant d'accepter de participer.

Discussion

Discussion communautaire

Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.